SAILIFEBSESai Life Sciences LtdMinimalNeutral
Announced Fri, 15 May · 14:39 IST

Monitoring Agency Report for the quarter and year ended 31 March 2026.

SAILIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.8%1-day move
₹1119.00
prior close
₹1103.80
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.7-0.5-0.0-0.5+0.8+0.8+2.7+1.7-1.2+1.7+6.1+7.5+13.0
Up moveDown movePending
AI summary

CRISIL Ratings Limited, the appointed Monitoring Agency, has submitted its report on the utilization of IPO proceeds for Sai Life Sciences Limited for the quarter and year ended March 31, 2026. The IPO, which closed in December 2024, raised Rs 30,426.20 million (fresh issue of Rs 9,500 million plus OFS of Rs 20,926.20 million). Of the Rs 9,500 million gross proceeds, Rs 9,444.72 million has been utilized so far, with Rs 55.28 million remaining unutilized. The two main objects — repayment of borrowings (Rs 7,200 million) and general corporate purposes (Rs 1,898.84 million) — have been fully utilized as per the offer document. Only Rs 55.28 million towards issue expenses remains unspent, parked in fixed deposits (Rs 36.97 million) and the public offer account (Rs 18.21 million). No utilization occurred during this quarter, and no deviations from the stated objects were observed.

Likely market impact

Shareholders can note that IPO funds are being deployed as disclosed in the offer document, with no material deviations or delays reported. The remaining Rs 55.28 million is appropriately held in liquid instruments pending final settlement of issue expenses.